Drug Trial Radar · NCT06392659
A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Aug 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
May 2, 2024
Primary completion
Jul 2, 2024
Study completion Jul 2, 2024
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Apr 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacokinetics (PK), drug-drug interaction, and safety and tolerability of VX-993 in healthy participants.
Conditions
- Pain
Interventions
VX-993Drug
Suspension for Oral Administration.
GemfibrozilDrug
Tablets for Oral Administration.
ItraconazoleDrug
Capsules for Oral Administration.
MidazolamDrug
Solution for Oral Administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum Observed Plasma Concentration (Cmax) of Midazolam in Absence or Presence of VX-993Time frame: Pre-dose up to Day 15
- Part A: Maximum Observed Plasma Concentration (Cmax) of 1-Hydroxy-Midazolam in Absence or Presence of VX-993Time frame: Pre-dose up to Day 15
- Part A: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in Absence and Presence of VX-993Time frame: Pre-dose up to Day 15
- Part A: Area Under the Concentration Versus Time Curve (AUC) of 1-Hydroxy-Midazolam in Absence and Presence of VX-993Time frame: Pre-dose up to Day 15
- Part B: Maximum Observed Plasma Concentration (Cmax) of VX-993 in Absence or Presence of ItraconazoleTime frame: Pre-dose up to Day 27
- Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-993 in Absence or Presence of ItraconazoleTime frame: Pre-dose up to Day 27
- Part C: Maximum Observed Plasma Concentration (Cmax) of VX-993 in Absence or Presence of GemfibrozilTime frame: Pre-dose up to Day 27
- Part C: Area Under the Concentration Versus Time Curve (AUC) of VX-993 in Absence or Presence of GemfibrozilTime frame: Pre-dose up to Day 27
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MAC Clinical Research
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.